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Abstract
Background: Uveitis involving the posterior segment is a significant and potentially blinding condition. The
diagnosis and treatment of patients with uveitis associated with tuberculosis remains controversial, and commonly,
patients are systemically well. Use of the interferon-gamma release assays has added to the controversy, as the
significance of a positive test may be uncertain. We aim to report the outcomes of anti-tuberculous treatment in a
cohort of patients treated in Birmingham, for presumed “ocular tuberculosis”, based on clinical findings, systemic
assessment and specific testing for tuberculosis.
Results: We found that in our cohort of 41 patients treated between 2010 and 2014, the majority achieved disease-
free remission, even in cases where anti-tuberculous treatment was delayed.
Conclusions: Despite controversy, this study strongly supports the use of anti-tuberculous therapy in such patients
and highlights the need for formal prospective trials and treatment protocols.
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Background
Intraocular inflammation, generally termed “uveitis”,
may result from a hugely diverse range of causes, both
infectious and non-infectious. Uveitis is classified by the
predominant anatomical site of inflammation within the
eye [1], the cause and whether or not it is related to an
infectious agent or an underlying systemic condition [2].
Uveitis is an important cause of visual loss, often affecting
the working age population [3, 4].
Uveitis related to tuberculosis is a well-recognized clin-
ical entity, with an extensive literature dating back more
than 100 years [5]. In some parts of the world, tuberculosis
is one of the principle causes of uveitis [6–9].
Currently, a large proportion of patients in the developed
world is described as having “non-infectious”, “idiopathic” or
“undifferentiated” uveitis [10, 11]. Often no underlying sys-
temic association or infection is identified despite extensive
investigation. If such patients have significant or “sight-
threatening” uveitis, they are generally treated with systemic
corticosteroid, and sometimes systemic immunosuppres-
sion, including biologics [12, 13]. Such therapy is aimed at
preventing relapses, as each relapse carries a risk of irrevers-
ible visual loss, morbidity and ocular complications [14].
The association between uveitis and “latent” or occult
tuberculosis is not new yet has become increasingly rele-
vant. Many patients display clinical appearances identical
to those seen in patients with active TB, without demon-
strating systemic manifestations of infection. Ocular
appearances associated with TB are heterogeneous, making
diagnosis challenging, and include (among others) choroi-
ditis, serpiginous-like choroiditis, granulomatous uveitis,
retinal vasculitis and intermediate uveitis [15]. In addition,
the condition known as “Eales” disease, a bilateral occlusive
retinal vasculitis, with minimal inflammation and often
complicated by vitreous haemorrhage, is observed more
frequently in TB-endemic populations.
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A large proportion of the global population will have
immunological evidence of latent TB, and consequently,
a significant proportion of patients with ocular inflammation
will have evidence of latent TB, whether or not it is causal.
Studies investigating intraocular samples provide support
for a central role of TB. Analysis of the aqueous humor,
vitreous gel or epiretinal membranes using polymerase
chain reaction (PCR) methods [16–20] demonstrates that
a higher proportion of samples from uveitis patients are
positive for the TB genome compared with samples taken
from patients in a similar population undergoing surgery
for other reasons, and a positive PCR result correlates
with a clinical response to anti-tuberculous treatment
(ATT) [19, 20].
Traditionally, the tuberculin skin test (Mantoux) has
been used to determine whether a patient is infected
with TB. The test may be affected by multiple factors,
making it hard to determine its significance. More recently,
interferon gamma release assays (IGRAs) have added
significant controversy to the diagnosis and management
of “ocular TB” [21–26]. Such assays, including the T-spot
or QuantiFERON GOLD tests rely on the observation that
T-cells will release interferon gamma when exposed to a
specific TB antigen. The test is highly specific and not
affected by previous BCG vaccinations. A positive IGRA
test usually indicates that a patient has been exposed to
TB; however, it cannot distinguish between latent infection
and active disease.
Multiple recent reports support the use of anti-
tuberculous therapy (ATT) in patients with a consistent
uveitic phenotype and positive TB investigations [27–30].
There is a lack of consensus regarding treatment indica-
tions, treatment regimens, investigation protocols and what
constitutes a successful outcome. Even the diagnosis of
“ocular TB” is not standardized [31].
Importantly, the way in which patients are managed is
believed to differ significantly between units, with some
uveitis specialists unable to persuade the respiratory
physician of the relevance of tuberculosis, whilst other
specialists are able to access anti-TB treatment easily
and as a result have a very low treatment threshold [32].
Some uveitis specialists elect to refer patients for ATT
only if the uveitis is severe, whilst continuing to treat
“mild” recurrent anterior uveitis with topical steroid.
The principle indication for using ATT in uveitis is to
treat the underlying systemic drive, which is believed to
come from occult infection, antigenic mimicry or a hyper-
sensitivity-type reaction to TB antigen. A secondary indica-
tion may be to ensure that systemic immunosuppression is
safe in the face of a positive T-spot result. This is especially
relevant for patients started with anti-TNF therapy [33].
The Birmingham and Midland Eye Centre is located
in an inner-city part of Birmingham where the large
surrounding population comprises of ethnically diverse
communities with a majority of people originating from
Southeast Asia, especially countries such as Pakistan,
India and Bangladesh, where the prevalence of TB is high.
Aims and objectives
The aims of this study were first, to define and report
the treatment outcomes of patients, who received anti-
tuberculous therapy for uveitis, and second, to characterize
the patient cohort seen at the Birmingham and Midland
Eye Centre who were diagnosed as having ocular TB.
Methods
This was a retrospective evaluation of patient notes. Ethical
approval was not required as the project was deemed to be
a service evaluation.
Using the regional TB disease register obtained from the
regional infectious diseases department, patients who had
been diagnosed as having uveitis related to TB and who
were started on ATT between 2010 and 2014 were identi-
fied. Patients who completed a course of treatment and
were followed up for at least 12 months were included in
the study.
A retrospective analysis of patient notes was undertaken.
Ethical approval was not required as this was deemed to
be a service evaluation and made use of anonymized retro-
spective patient information. Data pertaining to patient
characteristics, uveitis phenotype, vision, duration of
uveitis prior to therapy, date of commencement of
ATT, treatment details, duration of follow-up and
disease activity were collected. Data were also collected
regarding systemic investigations for TB.
At presentation to the uveitis service, patients under-
went a full ophthalmic examination and were assessed
with regard to the site and severity of their uveitis, using
the SUN criteria [1]. A full systemic workup was under-
taken, and patients underwent an extensive panel of
investigations, with the aim of excluding other causes.
All underwent chest radiograph or CT scan, with most
also undergoing Mantoux testing or interferon gamma
release assay, usually using T-spot. Investigations were
not protocolized, and patients were investigated appro-
priately in an individualized fashion.
A consistent ocular phenotype, together with findings
on chest imaging and/or positive T-spot or Mantoux
testing, with the exclusion of other causes of uveitis, led
to a diagnosis of presumed ocular TB.
Following this diagnosis, patients were referred ur-
gently to the respiratory team where they were inves-
tigated further as necessary. Throughout the course
of the study, the availability and use of interferon
gamma release assays increased. This meant that some
patients were not diagnosed with TB-related uveitis
until a significant period of ocular inflammation had
lapsed.
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In most patients, disease activity was observed as a
number of relapses, rather than continual inflammation.
Treatment with anti-inflammatory medication, mainly
corticosteroids, was used. These were administered
topically, peri-ocularly or systemically. Relapse on with-
drawal of therapy warranted repeat treatment.
Ocular disease activity was quantified using the number
of “flare-ups” of uveitis. A uveitis “flare” was defined as the
need for augmentation of treatment, with high-dose oral
steroid (usually at least 40 mg daily tapered over several
weeks), intravenous steroid, periocular steroid or hourly
topical steroid. Where possible, “flare rate” prior to ATT
was defined as the number of flare-ups per unit time of
disease. Calculating a “flare rate” was not possible if a
patient was treated with ATT immediately or had a very
short duration of disease prior to ATT.
Statistical methods
Data were reviewed using descriptive statistics. The “time
to flare” post-treatment was calculated using Kaplan-Meier
survival curves. Remission was defined as the absence of
flare-ups for at least 6 months whilst long-term remission
was defined as at least 12 months of disease quiescence
after completion of therapy. Flare rates were compared
before and after therapy using the Wilcoxon signed
rank test.
Results
Demographics
A total of 54 patients were identified as having uveitis
related to ocular TB and for whom treatment was recom-
mended. Of these, 41(76%) patients completed therapy and
complied with follow-up for at least 12 months. The
remainder either did not complete therapy, did not comply
with follow-up or both. The characteristics of the initial
patient cohort are described in Table 1. The majority of
patients were male, of Asian or Black ethnicity with a
mean age of 44 years.
Ocular disease
Uveitis was predominantly bilateral with most having
disease affecting the posterior segment. Isolated retinal
vasculitis, including the “Eales’ phenotype”, was categorized
as posterior uveitis. A wide range of uveitic phenotypes was
observed, including granulomatous anterior uveitis, retinal
vasculitis, nodular scleritis, choroiditis and intermediate
uveitis.
The date of first presentation with uveitis preceded the
diagnosis of TB-related eye disease in the majority, with
four patients starting ATT at the same time as their uveitis
was diagnosed. The duration of disease prior to ATT
ranged from 8 to 4495 days (more than 12 years) with a
median of 12 months. Prior to ATT, 31 patients were on
maintenance therapy for uveitis as described in Table 1.
Investigations to support the diagnosis of active or latent
tuberculosis
Data regarding the results of investigations arranged
from the uveitis clinic are shown in Table 2. It is seen
that a large proportion of patients (29) were referred for
ATT for ocular TB mainly on the basis of a positive
Mantoux and/or T-spot result, with normal chest X-ray
imaging and no systemic symptoms.
ATT regimens, duration and compliance
Of the 54 patients in whom treatment was recommended,
7 (13%) patients did not comply. The remaining 47
patients received a course of ATT. Duration of therapy
Table 1 Characteristics of the patient cohort
Gender (number of patients (%))
Male 33 61%
Female 21 39%
Age, years, mean (range) 44 (17–69)
Ethnicity (number of patients (%))
Asian 31 57%
Black 11 20.37%
Not specified 12 22.22%
Diabetic (number of patients (%)) 8 14.81%
Site of uveitis (number of patients (%))
Anterior 6 (11.11%)
Intermediate 15 (27.78%)
Posterior 12 (22.22%)
Panuveitis 19 (35.19%)
Other 2 (3.70%)
Bilateral disease (number of patients (%)) 41.58(77%)
Uveitis features present (NB some patients may have had more than
one feature)
Nodular scleritis 1
Choroiditis 7
Granulomatous anterior uveitis/ mutton fat KP 7
Retinal vasculitis 5
Panuveitis 13
Intermediate uveitis 18
Not recorded 3
Maintenance treatment prior to ATT Number of patients (%)
Unknown 8 (14.80)
Nil 13 (24.10)
Topical steroid alone 20 (37)
Oral steroid alone 3 (5.60)
Oral steroid and immunosuppression 2 (3.70)
Topical steroid and immunosuppression 1 (1.90)
Topical and systemic steroid 7 (13)
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ranged from 4 to 12 months with a mean of 6.8 months.
Treatment regimens varied; however, all patients received
rifampicin, with 9 receiving rifampicin, isoniazid and
pyrazinamide (RHZ) and 27 received RHZ and etham-
butol (E). See Table 3.
Disease activity following completion of therapy
Of the 47 patients who complied with ATT, follow-up
data were available for 41, with the remaining patients not
attending follow-up or having missing data. Duration of
clinic follow-up ranged from 20 to 2192 (median 557)
days with five patients being lost to follow-up or who
had moved elsewhere. Patients completing therapy were
instructed to attend eye casualty in the event of flare-up,
and it was assumed that their disease remained quiescent if
no attendances were recorded. The mean clinic follow-up
was 808 days.
A Kaplan-Meier survival curve for the 41 patients with
post-ATT follow-up data is shown in Fig. 1a. The survival
curve shows 90% of patients (39) were flare free 6 months
following ATT treatment and 80% (33) remained quiescent
for 12 months.
A survival curve including patients for which both
pre- and post-treatment data was available is shown in
Fig. 1b. This highlights that 94% of patients were flare
free at 6 months and 86% were flare free at 12 months.
The data set was then divided into two groups, those
patients who were treated with ATT within 8 months of
their first uveitis episode (group 1) and the remaining
(group 2) who had had a diagnosis of uveitis for more
than 8 months. This was to see whether patients with a
longer duration of uveitis were less likely to respond
favorably to ATT. Kaplan-Meier and log-rank tests (shown
in Fig. 1c) were used for analysis. No significant difference
in the time to flare was found (P = 0.565 log-rank) between
the two groups.
The monthly flare rate pre-ATT treatment was calcu-
lated from the first uveitis episode to initiation of ATT.
It was assumed the nine patients with a very short time
to treatment (< 4 months) would have had just one flare
in the time period. Post-treatment flare rates were calcu-
lated from time of ATT completion to last day of data
collection (December 2016). Flare rates after ATT were
significantly lower than those before (Wilcoxon signed
rank P = 0.000).
The data was further split into two groups; group 1
included patients treated within 8 months of their first
uveitis flare. Group 2 included those who were treated
more than 8 months after their first uveitis flare. Flare rates
post-ATT treatment for both groups were significantly
lower than pre-ATT (Wilcoxon signed rank P = 0.000,
P = 0.000 respectively).
To assess whether the short time to treatment following
first uveitis episode had an overall effect on the significant
difference in pre- and post-ATT flare rates, the nine
patients with less than 4 months follow-up were excluded
and the data re-analysed. The post-ATT flare rates
remaining significantly lower following the exclusion of
these patients (P = 0.000 Wilcoxon signed rank). Of the
nine patients excluded, all were flare free at 12 months.
Disease flare rates were also calculated using rates
per person year (PPY). Prior to ATT treatment, the
flare rate was 0.69 while after ATT, this reduced to
0.14. The difference was statistically significant (P =
0.000 mid-P exact).
Discussion
The principal finding from this study is that ATT in a
real-life clinical setting appears to significantly reduce
the number of flare-ups and to enable long-term remis-
sion in patients with presumed ocular tuberculosis. This
beneficial effect appears to persist even in patients who
experienced a long delay between the onset of uveitis
and the diagnosis of ocular TB.
Table 2 Investigations to support TB
Number of patients
No details available 4
Chest CT changes 4
With positive T-spot or Mantoux test 3
Positive Mantoux alone 15
Positive T-spot alone 12
Positive T-spot and Mantoux test 2
Typical X-ray changes present 6
With a positive T-spot and/or Mantoux test 6
Systemic symptoms presenta 11
With a positive T-spot and/or Mantoux test 7
With consistent CT or Chest X-ray findings 3
aOne patient underwent a bone marrow biopsy which confirmed
mycobacterium tuberculosis
Table 3 Treatment regimens
R alone 2
R + E 2
R + Z 1
RHZ 9
REZ 3
RHZE 27
Anti-TB (unknown specific treatment) 3
Additional prednisone 37
Non-compliant 7
Mean duration of therapy 6.8 months (range 4–12)
*Rifampicin R, isoniazid H, pyrazinamide Z, ethambutol E
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The patient cohort is diverse and strict diagnostic criteria
are absent, requiring a high degree of clinical judgment
and collaboration between specialists when treating such
patients.
The study has limitations in view of the “real-life” clinical
setting. Many were lost to follow-up or non-compliant
with ATT. “Flare rate” was used as a measure of disease
activity but may not accurately reflect disease in patients
with ongoing activity, where uveitis is chronically uncon-
trolled, or being suppressed with corticosteroid. ATT was
not standardized, and consequently, patients received a
range of regimens. The majority however received at least
6 months of therapy. There is evidence to support treating
patients for at least 9 months [29] although a wide range
of treatment regimens and durations is reported in the
literature.
Recent studies investigate therapeutic outcomes and the
beneficial effects of ATT. One meta-analysis concluded
that ATT in the management of patients with presumed
ocular TB enabled remission in 84% [30]. Another large
analysis explored whether any factors were associated with
a poorer outcome and found that prior immunosuppres-
sion and/or a high absolute QuantiFERON GOLD level
were associated with poorer resolution of inflammation
post-ATT or an ongoing need for systemic steroid [34].
This study highlights challenges and controversies in
defining outcomes in such cohorts. We attempted to
look at therapeutic outcomes in a number of ways,
including comparing flare rates pre and post, reporting
time to flare using Kaplan-Meier survival curves and
also calculating “flare rates” before and after treatment.
We also recognize that such measures may introduce
bias and favour a benefit in patients with a short period
of disease prior to the use of ATT. For this reason, we
compared results between patients with a long duration
of disease and a shorter duration of disease prior to
ATT. Despite some patients experiencing significant
delays in being started on ATT, we showed that such
patient still displayed a clear benefit from treatment.
We did not report visual outcomes or complications.
Whilst we show that there is a significant treatment
benefit, even when duration of uveitis is long, patients
with longer disease courses prior to ATT will be more
likely to suffer visual loss and complications. Therefore,
early treatment should be recommended [35].
Conclusions
In conclusion, this retrospective study shows that despite
the unresolved controversies regarding diagnosis, the
relevance of interferon gamma assays and what exactly
ocular tuberculosis is, if patients have a consistent uveitis
phenotype and other uveitic causes are excluded, then
ATT is likely to have a beneficial effect.
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